Shearman & Sterling advised Boston Scientific Corporation, as issuer, on an aggregate $1.7 billion registered offering of Senior Notes, comprised of two tranches: $500.0 million 1.900% notes due 2025 and $1.2 billion 2.650% notes due 2030.  Boston Scientific intends to use the net proceeds from this offering towards refinancing $450.0 million of borrowings under its revolving credit facility and a portion of its pre-payable bank debt, including $750.0 million under its $1.0 billion term loan credit facility maturing in February 2021 and $500.0 million under its $1.25 billion term loan credit facility maturing in April 2021 and paying related fees, expenses and premiums.

Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties.

The Team